Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DTIL

Precision BioSciences, Inc.

Healthcare | Biotechnology

Market prices for DTIL are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Precision BioSciences, Inc. (NASDAQ: DTIL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:46 UTC.

What Precision BioSciences, Inc. does

The company is a clinical-stage gene editing firm developing therapies using its proprietary ARCUS platform technology. ARCUS works by cutting DNA at specific locations to make insertions, eliminations, or excisions, and differs from competing technologies through its unique cutting mechanism, smaller size, and simpler single-component structure that requires no guide RNA. The company is advancing two clinical-stage in vivo gene editing programs, including PBGENE-HBV, which targets chronic hepatitis B by eliminating the viral DNA that persists in liver cells and currently has no cure.

Summarized from Precision BioSciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-49.57%

Revenue, margins & earnings

FY2021: net loss $31M on revenue $116M$116MFY2021FY2022: net loss $112M on revenue $25M$25MFY2022FY2023: net loss $61M on revenue $49M$49MFY2023FY2024 Revenue: $69M — margin split not shown (non-operating gains)$69MFY2024FY2025: net loss $46M on revenue $34M$34MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-30
  • 2026-09-30DirectorPurchase1,000$6.0K
  • 2026-09-29DirectorPurchase2,609$16.4K
  • 2026-09-29DirectorPurchase1,135$7.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Precision BioSciences, Inc. do?

The company is a clinical-stage gene editing firm developing therapies using its proprietary ARCUS platform technology.

When did DTIL last file with the SEC?

Precision BioSciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:46 UTC. This page is also available as JSON at /api/data?ticker=DTIL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DTIL and 5,000+ tickers.

Create a free account — keep DTIL
For your agent
GET /api/data?ticker=DTIL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt